About Prof. Huang Hefeng
Prof. Huang Hefeng is Director of the International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, and one of China's foremost authorities on assisted reproductive technology, prenatal genetic screening, and intergenerational reproductive health. His landmark research spans epigenetic mechanisms of transgenerational disease transmission (Nature, 2022), ICSI indication optimisation (The Lancet, 2024), and comprehensive cfDNA screening for single-gene disorders (Nature Medicine, 2024) — work adopted by the WHO and incorporated into international clinical guidelines.
Case Overview
Ms. Wu (pseudonym), a 32-year-old woman of Southern Chinese origin, presented at 11 weeks of gestation following a spontaneous conception. Standard NIPT had returned a low-risk result for chromosomal aneuploidies. Her obstetrician, aware of the limitations of standard NIPT for single-gene disorders, referred her to Prof. Huang's centre for comprehensive cfDNA screening using the COATE-seq platform at 12 weeks. The results identified a pathogenic beta-thalassaemia variant in fetal cfDNA consistent with compound heterozygosity — a finding standard NIPT cannot detect. Chorionic villus sampling confirmed fetal compound heterozygous beta-thalassaemia major (HBB: c.316-197C>T / IVS-II-654). After comprehensive genetic counselling, the couple elected to terminate the affected pregnancy and subsequently underwent IVF with preimplantation genetic testing (PGT-M). One euploid unaffected embryo was identified and transferred; Ms. Wu delivered a healthy male infant at 38+1 weeks, birthweight 3,210 g, Apgar 10/10, confirmed unaffected on neonatal genetic testing. Ms. Wu reflected: "The first test said everything was fine. It was only because our doctor referred us to Prof. Huang's centre that we found out the truth. It was the hardest thing we have ever faced — but knowing gave us the chance to have a healthy child. Our son is here, and he is well. We are grateful every day."
Diagnostic Workup
Standard NIPT at 11 weeks: low risk for trisomy 21, 18, and 13; single-gene disorders not screened. COATE-seq comprehensive cfDNA screening at 12 weeks: chromosomal and microdeletion panels negative; single-gene disorder panel identified a pathogenic beta-thalassaemia variant in fetal cfDNA consistent with compound heterozygosity (sensitivity 98.5%, specificity 99.3% in the validation cohort). Parental carrier testing confirmed: mother HBB IVS-II-654 carrier; father HBB CD41/42 carrier. CVS at 13+2 weeks confirmed fetal compound heterozygous beta-thalassaemia major — consistent with transfusion-dependent thalassaemia major if carried to term. Genetic counselling covered prognosis, management implications, and reproductive options in full.
Prof. Huang's diagnostic assessment: Standard NIPT screens for chromosomal copy number variants — it does not interrogate single-gene pathogenic variants. In a Southern Chinese couple, the prior probability of both partners being thalassaemia carriers is approximately 1 in 16. COATE-seq identified the fetal variant from maternal plasma at 12 weeks, before any invasive procedure, giving this couple the information they needed to make an informed decision.
Treatment Strategy and Course
Diagnosis: Fetal compound heterozygous beta-thalassaemia major — identified by COATE-seq at 12 weeks, confirmed by CVS at 13+2 weeks.
Treatment principle: comprehensive non-invasive prenatal identification of single-gene disorder, followed by informed reproductive decision-making and PGT-M IVF to achieve an unaffected pregnancy.
- COATE-seq and CVS: Pathogenic variant identified non-invasively at 12 weeks; CVS confirmation within one week; multidisciplinary genetic counselling including reproductive genetics, haematology, and psychology support
- PGT-M IVF: Ovarian stimulation, egg retrieval, ICSI fertilisation; trophectoderm biopsy of blastocysts; one euploid unaffected embryo identified from four biopsied
- Frozen embryo transfer: Single unaffected embryo transferred; positive beta-hCG at 14 days; fetal heartbeat confirmed at 7 weeks
- Delivery: Uncomplicated pregnancy; healthy male infant at 38+1 weeks, birthweight 3,210 g, Apgar 10/10; neonatal genetic testing confirmed unaffected HBB genotype
Prof. Huang's clinical reflection: Standard NIPT returned a negative result. Without COATE-seq, this couple would have continued the pregnancy unaware. The technology does not make the decision — it gives the family the information to make it themselves. That is what comprehensive prenatal screening is for.
Expert Commentary — Prof. Huang Hefeng
1. COATE-seq: Closing the Single-Gene Disorder Gap in Prenatal Screening
Standard NIPT detects chromosomal aneuploidies with high sensitivity but cannot interrogate single-gene pathogenic variants, leaving a significant diagnostic gap for conditions such as thalassaemia, Duchenne muscular dystrophy, and spinal muscular atrophy. COATE-seq simultaneously screens fetal cfDNA for chromosomal aneuploidies, microdeletion syndromes, and single-gene disorders in a single assay from a maternal blood draw at 10–14 weeks. In a prospective multicentre study of 1,191 high-risk pregnancies, COATE-seq detected pathogenic variants in 135 pregnancies (12.4%) — a 60.7% improvement over standard NIPT — with sensitivity 98.5% and specificity 99.3%. The technology is now incorporated into China's prenatal screening guidelines.
2. The Limits of Standard NIPT
A negative standard NIPT result does not exclude single-gene disorders. In populations with elevated carrier frequencies — Southern Chinese for thalassaemia, Mediterranean for beta-thalassaemia, Ashkenazi Jewish for Tay-Sachs and Gaucher disease — residual risk after a negative standard NIPT remains clinically significant. Comprehensive cfDNA screening with COATE-seq extends interrogation to the single-gene level from a single maternal blood draw, without the procedural risk of invasive testing as a first-line investigation.
3. ART Safety: Gamete-Origin Disease and ICSI Evidence
Prof. Huang's research extends to the safety of the reproductive environment itself. His Nature (2022) publication demonstrated that maternal hyperglycaemia induces epigenetic modifications in oocytes — aberrant TET3-mediated DNA demethylation affecting IGF2 expression — that increase diabetes susceptibility in offspring across generations, establishing the "gamete-origin disease" framework and supporting strict periconceptional glycaemic control in ART. His multicentre RCT in The Lancet (2024), enrolling 2,329 couples with non-severe male factor infertility, demonstrated that ICSI confers no advantage over conventional IVF in 12-month cumulative live birth rate (44.5% vs 50.9%; aRR 0.88, 95% CI 0.81–0.96), providing the evidence base for restricting ICSI to its validated indication.
How CMCS Shanghai Coordinated This Case
CMCS Shanghai supported Ms. Wu and her husband throughout their pathway at the International Peace Maternity and Child Health Hospital, providing priority consultation coordination with Prof. Huang's team, bilingual interpretation across all genetic counselling, CVS, and IVF consultations, psychological support coordination during the termination and IVF period, and bilingual communication of all results from COATE-seq through to neonatal genetic testing.
For international patients seeking comprehensive prenatal genetic screening, IVF with PGT, or specialist reproductive medicine consultation — particularly those from populations with elevated carrier frequencies for single-gene disorders — Prof. Huang Hefeng's team offers access to one of China's most advanced reproductive genetics programmes. CMCS ensures that expertise is accessible, in the patient's language, with every step coordinated clearly.
This case report is de-identified and published for educational purposes. All clinical details have been anonymized in accordance with patient privacy standards. CMCS Shanghai is a medical concierge service and does not provide direct medical care.
0 条评论